Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.

European journal of clinical pharmacology - 1 Sept 2009

Joy Melanie S, Dornbrook-Lavender Kimberly, Blaisdell Joyce, Hilliard Tandrea, Boyette Tammy, Hu Yichun, Hogan Susan L, Candiani Corina, Falk Ronald J, Goldstein Joyce A

Abstract excerpt

BACKGROUND: Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease (CKD). It is metabolized by cytochrome P450 (CYP) 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits. AIM: The s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C9

Share to Glomerular Filtration Rate

Share to Kidney Failure, Chronic

Share to Losartan

Share to Proteinuria

Source

Open in PubMed Open full text

Identifiers

PMID: 19669737
DOI: 10.1007/s00228-009-0707-7
PMCID: PMC2901912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19669737-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.PMID 19669737Read ↗

CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Pharmacogenomics of hypertension in chronic kidney disease: the CKD-PGX studySemantic proximity Read ↗

Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.Semantic proximity Read ↗

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.Semantic proximity Read ↗

Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9.Semantic proximity Read ↗

Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.Semantic proximity Read ↗

A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Semantic proximity Read ↗

Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.Semantic proximity Read ↗

Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.